… in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies
from the Spanish Germ Cell … Controversies in the management of clinical stage I seminoma: …

… Controversies in the management of clinical stage I seminoma: … in stage I seminoma: a new
nomogram derived from three consecutive, risk adapted studies from the Spanish Germ Cell …

… , patients with clinical stage I (CSI) testicular seminoma may … ter adjuvant carboplatin for
clinical stage I seminoma. J Clin … carboplatin for stage I testicular seminomatous germ cell tumour…

… , with 55 patients diagnosed with clinical stage I seminoma between … in stage I seminoma:
a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ …

… We analyzed all relapses observed in a series of 879 patients with stage I seminoma … , 879
patients with clinical stage I seminoma were included in four prospective, risk-adapted studies …

… the development of risk-adapted treatment strategy and stratification of patients in low-…
Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ …

… The relapse rate in patients with clinical stage I (CSI) seminomatous germ cell tumor of
the testis (SGCTT) who were undergoing surveillance after radical orchidectomy is 4–30%, …

… a risk-adapted strategy in this context [15]. The relapse rate for low-risk non-seminoma patients
is … study performed in the Medical Oncology Department of a Spanish University Hospital …

… , ∼85% of seminomas are diagnosed as clinical stage I disease as compared with 60…
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ …

… Option 3 was risk-adapted active surveillance (RAAS) based on a Spanish Germ Cell
Cancer Group protocol—patients with tumor size >4 cm and rete testis invasion received two …